Germany · Delayed Price · Currency is EUR Anixa Biosciences Company Description
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology.
Its therapeutics programs include the development of a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer.
The company’s vaccine programs include the development of a vaccine against breast cancer, initially focused on triple negative breast cancer (TNBC), the most lethal form of breast cancer; and the development of a vaccine against ovarian cancer, as well as a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate.
Its vaccine technologies focus on the discovery of additional retired proteins that may be associated with other forms of cancer.
The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018.
Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
| Country | United States |
| Founded | 1982 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 5 |
| CEO | Amit Kumar |
Contact Details
Address: 3150 Almaden Expressway San Jose, Delaware 95118 United States | |
| Phone | 408 708 9808 |
| Website | anixa.com |
Stock Details
| Ticker Symbol | CY71 |
| Exchange | Frankfurt Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | November - October |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Amit Kumar | Chief Executive Officer |
| Michael Catelani | Chief Financial Officer |
| Michael Catelani | Chief Operating Officer |